Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) - A phase II non-randomised trial

European Journal of Cancer

Volumn 50, Issue 18, 2014, Pages 3107-3115

  Mitry, Emmanuel ^a   Walter, Thomas ^b   Baudin, Eric ^c   Kurtz, Jean Emmanuel ^d   Ruszniewski, Philippe ^e   Dominguez Tinajero, Sophie ^f   Bengrine Lefevre, Leïla ^g   Cadiot, Guillaume ^h   Dromain, Clarisse ^c   Farace, Françoise ^c   Rougier, Philippe ⁱ   Ducreux, Michel ^c  

^a INSTITUT CURIE   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e BEAUJON HOSPITAL   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Bevacizumab; Capecitabine; Gastro intestinal neuroendocrine tumours; Metastatic

Indexed keywords

BEVACIZUMAB; CAPECITABINE; KI 67 ANTIGEN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLEEDING; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FACE ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL NEUROENDOCRINE TUMOUR; GASTROINTESTINAL TUMOR; HAND FOOT SYNDROME; HEALTH STATUS; HEART ARREST; HUMAN; HYPERTENSION; HYPOKALEMIA; INTESTINE OBSTRUCTION; LIVER GRAFT; MALE; MULTICENTER STUDY; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RESPIRATORY FAILURE; SEPTIC SHOCK; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VERY ELDERLY; WOUND HEALING IMPAIRMENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTROINTESTINAL NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; TREATMENT OUTCOME;

EID: 84925226890     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.10.001     Document Type: Article

References (34)

1. J.C. Yao, M. Hassan, and A. Phan One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 18 2008 3063 3072
2. K.K. Turaga, and L.K. Kvols Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors CA Cancer J Clin 61 2 2011 113 132
3. J.R. Eads, and N.J. Meropol A new era for the systemic therapy of neuroendocrine tumors Oncologist 17 3 2012 326 338
4. S. Faiss, U.F. Pape, and M. Bohmig Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 14 2003 2689 2696
5. A. Rinke, H.H. Muller, and C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 28 2009 4656 4663
6. D. O'Toole, and P. Ruszniewski Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours Best Pract Res Clin Gastroenterol 19 4 2005 585 594
7. B. Terris, J.Y. Scoazec, and L. Rubbia Expression of vascular endothelial growth factor in digestive neuroendocrine tumours Histopathology 32 2 1998 133 138
8. J. Zhang, Z. Jia, and Q. Li Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors Cancer 109 8 2007 1478 1486
9. M.E. Pavel, J.D. Hainsworth, and E. Baudin Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 9808 2011 2005 2012
10. M.H. Kulke, H.J. Lenz, and N.J. Meropol Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 20 2008 3403 3410
11. J.A. Chan, K. Stuart, and C.C. Earle Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors J Clin Oncol 30 24 2012 2963 2968
12. M.H. Kulke, J.A. Chan, and J.A. Meyerhardt A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors Cancer Chemother Pharmacol 68 2 2011 293 300
13. J.C. Yao, A. Phan, and P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 8 2008 1316 1323
14. P.L. Kunz, T. Kuo, and J.M. Zahn A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors [abstract] J Clin Oncol 28 suppl. 15 2010 4104
15. I. Firdaus, K.C. Shih, and A. Zakari Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET) [abstract] J Clin Oncol 30 suppl. 15 2012 4127
16. J.C. Yao, C. Lombard-Bohas, and E. Baudin Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 1 2010 69 76
17. J. Feliu, M.J. Safont, and A. Salud Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Br J Cancer 102 10 2010 1468 1473
18. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2 2004 145 147
19. H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 3 2005 671 680
20. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
21. P. Osterlund, L.M. Soveri, and H. Isoniemi Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy Br J Cancer 104 4 2011 599 604
22. J.P. Boudreaux, D.S. Klimstra, and M.M. Hassan The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum Pancreas 39 6 2010 753 766
23. W. Sun, S. Lipsitz, and P. Catalano Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 22 2005 4897 4904
24. L. Dahan, F. Bonnetain, and P. Rougier Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710 Endocr Relat Cancer 16 4 2009 1351 1361
25. T.J. Hobday, J. Rubin, and K. Holen MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study [abstract] J Clin Oncol 25 18S 2007 4504
26. A.T. Phan, J.C. Yao, and D.R. Fogelman A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) [abstract] J Clin Oncol 28 7S 2010 4001
27. E. Grande, D.E. Castellano, and R. Garcia-Carbonero PAZONET: a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients, on behalf of the Spanish task force for NETS (GETNE) ESMO 2012 Abstract 1157O
28. J.C. Yao, J.X. Zhang, and A. Rashid Clinical and in vitro studies of imatinib in advanced carcinoid tumors Clin Cancer Res 13 1 2007 234 240
29. I. Duran, J. Kortmansky, and D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 9 2006 1148 1154
30. J.C. Yao, A.T. Phan, and D.Z. Chang Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 26 2008 4311 4318
31. J.C. Yao, C. Ng, and P.M. Hoff Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract] J Clin Oncol 23 suppl. 16 2005 4007
32. S.M. Bison, M.W. Konijnenberg, and M. Melis Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments Clin Transl Imaging 2 2014 55 66
33. M.H. Kulke, L.L. Siu, and J.E. Tepper Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting J Clin Oncol 29 7 2011 934 943
34. T. Walter, and M.K. Krzyzanowska Quality of clinical trials in gastroenteropancreatic neuroendocrine tumours Neuroendocrinology 96 3 2012 238 248